|
Day 1
Friday, 6 September 2024 (1.30pm to 8.30pm)
|
|
Time
|
Title
|
Speakers
|
|
12.30pm to 1.30pm
|
Registration
|
|
|
1.30pm to 1.45pm
|
Welcome and Opening Remarks
|
Dr. Mohamed Salem Al-Hassan
CEO & Medical Director, NCCCR Chairman, Corporate Cancer Services, HMC
Dr. Mohammed Ussama Al Homsi
Deputy Medical Director for Education, Research and Quality, Senior Consultant Medical Oncologist, NCCCR
|
|
Session 1 - Moderators: Dr. Asma El
Hassan & Dr. Mohamed Siralkhatim
|
|
1.45pm to 2.05pm
|
Melanoma/Skin Cancers/Sarcoma
(Abstract LBA2): Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial
|
Dr. Asma El Hassan
Senior Consultant Medical Oncologist, NCCCR
|
|
2.05pm to 2.25pm
|
Melanoma/Skin Cancers/Sarcoma
(Abstract LBA9503): Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN)
|
Dr. Ashraf Awadelkarim
Associate Consultant Medical Oncologist, NCCCR
|
|
2.25pm to 2.40pm
|
Melanoma/Skin Cancers/Sarcoma
(Abstract 9500): Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
|
Dr. Mutie Ullah Ahmed
Clinical Fellow, Oncologist, NCCCR
|
|
2.40pm to 2.55pm
|
Melanoma/Skin Cancers/Sarcoma
(LBA9512): Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial
|
Dr. Mohamed Aboagla
Clinical Fellow, Oncologist, NCCCR
|
|
2.55pm to 3.10pm
|
PANEL DISCUSSION
|
|
3.10pm to 3.30pm
|
Prayer and Coffee Break
|
|
Session 2 - Moderators: Dr. Salha
Bujassoum & Dr. Mufid El Mistiri
|
|
3.30pm to 3.50pm
|
Breast Cancer - Metastatic
(Abstract 1021): TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2
|
Dr. Salha Bujassoum
Chair of Medical Oncology and Palliative Care, Senior Consultant Medical Oncologist, NCCCR
|
|
3.50pm to 4.10pm
|
Breast Cancer - Metastatic
(Abstract LBA1000): Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)
|
Dr. Khalid Al-Baimani
Senior Consultant Medical Oncologist,
Head of Medical Oncology Department,
Sultan Qaboos Comprehensive Cancer
Care and Research Center, Oman
|
|
4.10pm to 4.30pm
|
Breast Cancer - Metastatic
(Abstract 1007): Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD)
|
Dr. Francois Calaud
Senior Consultant Medical Oncologist, NCCCR
|
|
4.30pm to 4.50pm
|
Breast Cancer - Local/Regional/Adjuvant (Abstract LBA502): Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)
|
Dr. Abdulwahab Al-Tourah
Consultant Medical Oncologist,
Head of Medical Oncology,
Kuwait Cancer Control Center, Kuwait
|
|
4.50pm to 5.10pm
|
Breast Cancer - Metastatic
(Abstract LBA1001): Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial
|
Dr. Ahlam Yousif
Consultant Medical Oncologist, NCCCR
|
5.10pm to 5.30pm
|
Breast Cancer - Local/Regional/Adjuvant
(Abstract LBA500): A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy
|
Prof. Humaid Al-Shamsi
CEO of Burjeel Cancer Institute,
President of Emirates Oncology Society, UAE
|
|
5.30pm to 5.50pm
|
PANEL DISCUSSION
|
|
5.50pm to 6.10pm
|
Prayer and Coffee Break
|
|
Session 3 – Moderators: Dr. Francois Calaud & Dr. Hind
El Malik
|
6.10pm to 6.30pm
|
Breast Cancer - Local/Regional/Adjuvant
(Abstract 505): Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)
|
Dr. Mufid El Mistiri
Senior Consultant Medical Oncologist, NCCCR
|
|
6.30pm to 6.50pm
|
Breast Cancer - Local/Regional/Adjuvant
(Abstract LBA507): Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)
|
Dr. Cicy Mary Jacob
Consultant Medical Oncologist, NCCCR
|
|
6.50pm to 7.10pm
|
Breast Cancer - Metastatic
(Abstract LBA1002): Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL
|
Dr. Mohammed Gaber
Medical Oncologist, NCCCR
|
|
7.10pm to 730pm
|
Gynecologic Cancer
(Abstract 5511): Final A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer
|
Dr. Hind El Malik
Senior Consultant Medical Oncologist, NCCCR
|
|
7.30pm to 7.50pm
|
Gynecologic Cancer
(Abstract 5506): Phase II randomized multi-centre study of neoadjuvant Olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.
|
Dr. Shaza Bek
Medical Oncologist, NCCCR
|
|
7.50pm to 8.10pm
|
Gynecologic Cancer
(Abstract 5504): Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724.
|
Dr. Suparna Chandramouli
Associate Consultant Radiation Oncologist, NCCCR
|
|
8.10pm to 8.25pm
|
PANEL DISCUSSION
|
|
8:25pm to 8:30pm
|
Day 1 Closing Remarks
|
|
8.30pm
|
Dinner
|
